TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25057276

Group type: EXPERIMENTAL
Intervention: pterostilbene 125 mg twice daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: pterostilbene 50 mg twice daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: pterostilbene 50 mg + grape extract (GE) 100 mg twice daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: high dose pterostilbene
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: pterostilbene
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 25058217

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) with alemtuzumab (1 mg/kg), total-body irradiation (300 cGy), sirolimus, and filgrastim mobilized peripheral blood stem cells (5.5-31.7 × 10(6) cells/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic HSCT
Number of subjects: 30
Study: 25058267

Group type: EXPERIMENTAL
Intervention: Peritoneal-serum lactate ratio greater than 4.5
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Peritoneal lactate value greater than 9.1 mmol/L
Number of subjects: 88
Study: 25058615

Group type: EXPERIMENTAL
Intervention: IL-17A production by CD146+ T cells in psoriatic blood and lesions
Number of subjects: 0
Study: 25059766

Group type: EXPERIMENTAL
Intervention: Preoperative magnetic resonance imaging (MRI)
Number of subjects: 199
Study: 25060819

Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide (FeNO) measurements
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care without FeNO
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Use of FeNO in addition to standard of care
Number of subjects: 50
Study: 25061140

Group type: COMPARATOR
Intervention: Type 2 diabetes patients
Number of subjects: 194

Group type: COMPARATOR
Intervention: Type 1 diabetes patients
Number of subjects: 194
Study: 25061149

Group type: EXPERIMENTAL
Intervention: Telemedicine for diabetes care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25061868

Group type: EXPERIMENTAL
Intervention: Maximal safe tumor resection
Number of subjects: 97

Group type: COMPARATOR
Intervention: Large residual tumors (> 3 cm³)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Large residual tumors
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Faster regrowth rate
Number of subjects: 97
Study: 25062507

Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DM/Q) 30/30 mg twice daily
Number of subjects: 553
Study: 25062744

Group type: EXPERIMENTAL
Intervention: HDL3-C
Number of subjects: 4932

Group type: EXPERIMENTAL
Intervention: HDL2-C
Number of subjects: 4932

Group type: EXPERIMENTAL
Intervention: HDL-C
Number of subjects: 4932
Study: 25062770

Group type: EXPERIMENTAL
Intervention: Decitabine 0.1 or 0.2 mg/kg three times weekly for 2 weeks, Panobinostat 10, 20, or 30 mg every 96 h, Temozolomide 150 mg/m(2)/day on days 9-13 (increased to 200 mg/m(2)/day in cycle 2 if no neutropenia or thrombocytopenia)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maintenance protocol with weekly panobinostat and thrice-weekly decitabine until tumor progression, unacceptable toxicity, or withdrawal of consent
Number of subjects: 20
Study: 25063332

Group type: EXPERIMENTAL
Intervention: PBT2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 25063541

Group type: EXPERIMENTAL
Intervention: Novel imaging techniques and biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New diagnostic criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapeutic strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life and clinical outcomes testing
Number of subjects: 0
Study: 25063544

Group type: EXPERIMENTAL
Intervention: Erythropoietin 33,000 IU intravenously on 3 consecutive days
Number of subjects: 0
Study: 25064025

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (400-1600 IU/d)
Number of subjects: 132
Study: 25064094

Group type: EXPERIMENTAL
Intervention: Pirfenidone (1200 mg/day) for 24 months
Number of subjects: 28
Study: 25064285

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) program for 12 weeks
Number of subjects: 134
Study: 25065380

Group type: EXPERIMENTAL
Intervention: Micro-focused ultrasound with visualization (MFU-V)
Number of subjects: 30
Study: 25065582

Group type: EXPERIMENTAL
Intervention: Focal junctional tourniquet (JT)
Number of subjects: 10
Study: 25066326

Group type: EXPERIMENTAL
Intervention: Occupational engagement at baseline
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Motivation for day centre activities
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Not preferring work before attending the day centre
Number of subjects: 108
Study: 25066363

Group type: EXPERIMENTAL
Intervention: Creon® Micro (5000 lipase units/spoon)
Number of subjects: 40
Study: 25066554

Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulants (NOACs)
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Management of anticoagulation surrounding bleeding events
Number of subjects: 15000
Study: 25067982

Group type: EXPERIMENTAL
Intervention: Olmesartan plus probenecid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Olmesartan alone
Number of subjects: 12
Study: 25067985

Group type: EXPERIMENTAL
Intervention: Cactus fiber (2 tablets thrice daily with main meals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (2 tablets thrice daily with main meals)
Number of subjects: 20
Study: 25069627

Group type: EXPERIMENTAL
Intervention: Opioids and/or acetaminophen (oral oxycodone and/or acetaminophen)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Opioids (total daily consumption)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Analgesic administration methods
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nausea, vomiting, pruritus, altered level of consciousness
Number of subjects: 200
Study: 25070153

Group type: EXPERIMENTAL
Intervention: Oral nicorandil (15 mg/d, nicorandil group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral nicorandil
Number of subjects: 100
Study: 25071871

Group type: EXPERIMENTAL
Intervention: Developmental skills assessment in classic RTT
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Developmental skills assessment in atypical RTT
Number of subjects: 638

Group type: COMPARATOR
Intervention: Comparison of skills acquisition between classic RTT and atypical RTT
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Generalized estimating equation for Motor Behavioral Assessment
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: General linear model for age of acquisition or loss of developmental skill
Number of subjects: 638
Study: 25072443

Group type: EXPERIMENTAL
Intervention: 7.5% saline with 6% dextran 70
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: 7.5% saline
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 2061

Group type: COMPARATOR
Intervention: Shock cohort
Number of subjects: 2061

Group type: COMPARATOR
Intervention: TBI cohort
Number of subjects: 2061

Group type: COMPARATOR
Intervention: Cohort with both shock and TBI
Number of subjects: 2061

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 2061
Study: 25072733

Group type: EXPERIMENTAL
Intervention: Detection of cyp51 A key mutations using PCR assays
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Detection of azole resistance in clinical isolates
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Novel PCR assay for cyp51 A 46 bp tandem repeat (TR46)
Number of subjects: 155
Study: 25072780

Group type: EXPERIMENTAL
Intervention: Y(90) ibritumomab tiuxetan and BEAM regimen followed by autologous stem cell transplantation (ASCT)
Number of subjects: 75
Study: 25072816

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: s-cTnI
Number of subjects: 441
Study: 25073894

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 30
Study: 25074036

Group type: EXPERIMENTAL
Intervention: Gemcitabine (800-1,000 mg/m² on days 1, 8, and 15, then every 3-4 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: S-1 (40-80 mg/m²/day on days 1-28, then every 3-6 weeks)
Number of subjects: 33
Study: 25074070

Group type: COMPARATOR
Intervention: Tree nuts
Number of subjects: 2226

Group type: COMPARATOR
Intervention: Control diet interventions
Number of subjects: 2226
Study: 25074375

Group type: EXPERIMENTAL
Intervention: Low SES neighborhoods
Number of subjects: 1557

Group type: COMPARATOR
Intervention: High SES neighborhoods
Number of subjects: 1557
Study: 25074459

Group type: EXPERIMENTAL
Intervention: Afatinib + Cetuximab
Number of subjects: 126
Study: 25074504

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 514
Study: 25074699

Group type: EXPERIMENTAL
Intervention: Set 1: Ѳ(Tp|Tref) >42°; Ѳ(Tinit|Tterm) >30°; STJ depression in V6; rate-adjusted QTp interval (QTpa)
Number of subjects: 52994

Group type: EXPERIMENTAL
Intervention: Set 2: TaVR amplitude >-100 μV; TV1 >175 μV; QRS duration >100 ms
Number of subjects: 52994
Study: 25075006

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Fondaparinux with unfractionated heparin (UFH)
Number of subjects: 1734
Study: 25075128

Group type: EXPERIMENTAL
Intervention: Afuresertib (125 mg per day, maximum tolerated dose)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Afuresertib (doses ranging from 25 to 150 mg per day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Afuresertib (doses > 75 mg)
Number of subjects: 73
Study: 25075804

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM vaccine
Number of subjects: 341
Study: 25075833

Group type: EXPERIMENTAL
Intervention: KAE609 (30 mg per day for 3 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral artesunate (not specified dosage or duration)
Number of subjects: 21
Study: 25075853

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25075930

Group type: EXPERIMENTAL
Intervention: Intrinsic motivation
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Increase in motivation during the 6-month follow-up
Number of subjects: 431
Study: 25076364

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 0.5 mL of bevacizumab (2.5 mg/0.1 mL)
Number of subjects: 36
Study: 25076495

Group type: EXPERIMENTAL
Intervention: Diets emphasizing tree nuts (median dose of 56 g/d)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control diets (isocaloric diets without tree nuts)
Number of subjects: 450
Study: 25077099

Group type: EXPERIMENTAL
Intervention: Immediate-release morphine sulfate syrup (initially 0.5 mg twice daily, titrated based on weekly assessments)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Immediate-release morphine sulfate syrup
Number of subjects: 44
Study: 25077107

Group type: EXPERIMENTAL
Intervention: Sufficient vitamin D levels (≥ 75 nmol/L)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Insufficient vitamin D levels (< 75 nmol/L)
Number of subjects: 173
Study: 25077537

Group type: EXPERIMENTAL
Intervention: Scanning laser ophthalmoscope reflectance imaging
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adaptive optics infrared flood imaging
Number of subjects: 18
Study: 25077901

Group type: EXPERIMENTAL
Intervention: VLDL1-apoB
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Liver fat
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: VLDL1-triglycerides (TGs) indirect FCR
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: VLDL1-TG production rate
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: apoA-II FCR
Number of subjects: 62
Study: 25078269

Group type: EXPERIMENTAL
Intervention: CD56+ lung lymphocytes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lung NK cells (CD56+ CD3-) and CD56+ T cells (CD56+ CD3+)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Autologous lung epithelial cells
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lung CD56+ cells
Number of subjects: 60

Group type: COMPARATOR
Intervention: CD4+ or CD8+ conventional lung T cells
Number of subjects: 60
Study: 25079400

Group type: EXPERIMENTAL
Intervention: Intensive oral hygiene regimen with oral hygiene products and non-surgical therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intensive oral hygiene regimen
Number of subjects: 120
Study: 25079603

Group type: EXPERIMENTAL
Intervention: HCV genotype 1 isolates from patients with slow disease progression
Number of subjects: 107

Group type: COMPARATOR
Intervention: HCV genotype 1 isolates from patients with rapid disease progression
Number of subjects: 107

Group type: COMPARATOR
Intervention: General assessment of viral genetic variation and HCC
Number of subjects: 107

Group type: COMPARATOR
Intervention: Assessment of amino acid distributions and selection pressures
Number of subjects: 107
Study: 25079662

Group type: EXPERIMENTAL
Intervention: Ethnic minorities (African Americans, Hispanics, Chinese Americans)
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Health status and modifiable diabetes-specific risk/protective factors (healthcare access/utilization, subjective diabetes burden, social support/burden)
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Adjustment for risk/protective factors
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Interactions between ethnicity and other correlates of psychological outcomes
Number of subjects: 1055
Study: 25080050

Group type: EXPERIMENTAL
Intervention: Isolated raised base excess (BE) (≥ 2 mmol/L)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Established OHS (awake hypercapnia > 6 kPa)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal blood gas measurements and normal acid-base balance
Number of subjects: 71
Study: 25080392

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 4987

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 4987

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4987
Study: 25080428

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric content by anaesthesiologists
Number of subjects: 32
Study: 25080540

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Anemia prevalence
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Iron deficiency (sTfR > 8.5 mg/L)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: IL-6 concentrations
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: EPO as an indicator of iron status
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: EPO explained variance in hemoglobin
Number of subjects: 253
Study: 25080553

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 217
Study: 25080874

Group type: EXPERIMENTAL
Intervention: Headache Impact Test (HIT-6)
Number of subjects: 1384
Study: 25081818

Group type: EXPERIMENTAL
Intervention: Engage
Number of subjects: 39

Group type: COMPARATOR
Intervention: Problem Solving Therapy (PST)
Number of subjects: 39
Study: 25082288

Group type: EXPERIMENTAL
Intervention: Semaphorin-plexin system targeting
Number of subjects: 0
Study: 25082342

Group type: EXPERIMENTAL
Intervention: Lenalidomide 2.5mg followed by 5.0mg continuous
Number of subjects: 37
Study: 25082885

Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for BEST1 in BMD patients
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for EFEMP1 in DHRD patients
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for TIMP3 in SFD patients
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for PRPH2 in PD patients
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for ABCA4 in PD patients
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for GUCY2D in CRD patients
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Mutation analysis by dideoxy sequencing for ABCA4 in CRD patients
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Overall genetic testing results
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Selective screening for mutations in BEST1, PRPH2, and ABCA4
Number of subjects: 213
Study: 25082970

Group type: EXPERIMENTAL
Intervention: Somatic dysfunctions (specifically right anterior innominate dysfunctions)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Somatic dysfunctions (specifically left superior shear)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Somatic dysfunctions (specifically left-on-left sacral torsion)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Somatic dysfunctions (specifically right anterior innominate rotation dysfunctions)
Number of subjects: 98
Study: 25083135

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 6000
Study: 25084088

Group type: EXPERIMENTAL
Intervention: Interventional MRI-guided deep brain stimulation (DBS) using the ClearPoint system
Number of subjects: 6
Study: 25084263

Group type: EXPERIMENTAL
Intervention: Positive airway pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25084608

Group type: EXPERIMENTAL
Intervention: Proton beam radiation therapy to the surgical bed, 40 Gy in 10 fractions, once daily over 2 weeks.
Number of subjects: 100
Study: 25085007

Group type: EXPERIMENTAL
Intervention: MAPP Network's integrated multi-disciplinary research approach
Number of subjects: 0
Study: 25085119

Group type: EXPERIMENTAL
Intervention: UCPPS participants
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Positive controls (NUAS criteria)
Number of subjects: 1039
Study: 25085333

Group type: EXPERIMENTAL
Intervention: Gastric volume reduction with an endoscopic stapler
Number of subjects: 17
Study: 25085385

Group type: EXPERIMENTAL
Intervention: CareWell in Hospital program
Number of subjects: 386
Study: 25085521

Group type: EXPERIMENTAL
Intervention: Pathologic amniotic fluid in normal birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Male sex in normal birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Birth season in low birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Maternal body temperature in low birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment at the time of labor in low birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Number of pregnancy consultations in low birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Maternal age in low birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Apgar score in low birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Infant convulsions in low birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Pathologic amniotic fluid in low birth weight infants
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Cesarean delivery in low birth weight infants
Number of subjects: 792
Study: 25085632

Group type: EXPERIMENTAL
Intervention: Sunitinib (Sutent) - a VEGFR2/PDGFRβ/c-kit/FLT3/RET/CSF1R inhibitor
Number of subjects: 5
Study: 25086446

Group type: EXPERIMENTAL
Intervention: Acceptance-based psychological coping
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control for age, education, and time since diagnosis
Number of subjects: 97
Study: 25086465

Group type: EXPERIMENTAL
Intervention: Imatinib, dacarbazine, and capecitabine regimen (imatinib 300 mg daily on days 1-21, dacarbazine 250 mg/m2 daily on days 1-3, capecitabine 500 mg/m2 twice daily on days 1-14)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imatinib, dacarbazine, and capecitabine regimen
Number of subjects: 20
Study: 25086913

Group type: EXPERIMENTAL
Intervention: Metformin (61.2%)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Insulin (18%)
Number of subjects: 983
Study: 25087103

Group type: EXPERIMENTAL
Intervention: HeartWare HVAD system
Number of subjects: 332
Study: 25087889

Group type: EXPERIMENTAL
Intervention: LEFt clinical decision rule (scoring system based on left leg suspicion, edema, and trimester)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: LEFt clinical decision rule
Number of subjects: 96
Study: 25090481

Group type: EXPERIMENTAL
Intervention: Baseline diabetic knowledge after five-day teaching program
Number of subjects: 79
Study: 25090645

Group type: EXPERIMENTAL
Intervention: AS03A-H5N1 vaccine (3.75μg hemagglutinin-antigen)
Number of subjects: 78
Study: 25091095

Group type: EXPERIMENTAL
Intervention: Viance peripheral CTO crossing device
Number of subjects: 58
Study: 25091263

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day on days 2-5, 9-12, 16-26 of each 28-day cycle plus gemcitabine 1000 mg/m(2) as an intravenous infusion over 30-min on days 1, 8, 15
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Erlotinib plus gemcitabine
Number of subjects: 30
Study: 25091537

Group type: EXPERIMENTAL
Intervention: Aztreonam for inhalation solution (AZLI) 75 mg 3 times daily for 28 days
Number of subjects: 105
Study: 25091619

Group type: EXPERIMENTAL
Intervention: Ixabepilone 40 mg/m² on day one of a 21 day cycle
Number of subjects: 26
Study: 25091629

Group type: EXPERIMENTAL
Intervention: Aerobic and/or resistance training programmes
Number of subjects: 112
Study: 25092772

Group type: EXPERIMENTAL
Intervention: Vemurafenib monotherapy
Number of subjects: 0
Study: 25092789

Group type: EXPERIMENTAL
Intervention: Greater left ventricular dyssynchrony (measured by standard deviation of time to peak systolic strain, SD-TPS) in women
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Greater left ventricular dyssynchrony (measured by SD-TPS) in women
Number of subjects: 1392
Study: 25092878

Group type: EXPERIMENTAL
Intervention: Regional Restitution Instability Index (R2I2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peak ECG Restitution Slope (PERS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: R2I2≥1.03
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: R2I2 and PERS positive
Number of subjects: 60
Study: 25093475

Group type: EXPERIMENTAL
Intervention: Brief pulse right unilateral electroconvulsive therapy (ECT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse right unilateral electroconvulsive therapy (ECT)
Number of subjects: 0